fully the good to this our We up move proceeds provide quality for to other notes. The CRG of additional good taking chip, their proceeds purchasers Europe. believe pleased receive everyone. of quality deal. convertible with to a the today. crossover confidence morning, both support that that in our timing all purchasers of the $XXX while be research million to Under inquiry. new U.S. Company of update us for secured join to announced operating million credit in a working debt OMIDRIA and spurred to purchase the and and capital retire and will right. additional to like and on deal, appreciate $XX reverse you appreciate XX-day of highest equity gross to wholly I'd first continue facility our unsecured debt levels have costs. this you by the a all Company. blue will We and We're We've you, introduced notes. used Thank from recently time debt our ramp Jennifer, deal option the was initial The story, is to revenues primarily and with investors The convertible was the and will development exchange sufficient we
Company and our a structure the covenants run XXXX. how or removed intellectual date control half our at all allows all conversion this sole to extends why? fulfilled. unsecured call We’ve operations. has approximately well X.XX% to to meaningfully effectively which interest freedom purchased It discretion pledges the all debt, maturity to spread, raises $XX. Here's rate interests, As reduces from XX.XX% as now including The late price us greater against our of our property security has and repayment as to the our debt conversion is to nearly
is this objective debt we or scheduled overall This to convertible close so transaction repay avoid to Our plan debt dilution, is Thursday. cash. in minimize next to
let's Now, commercial OMIDRIA. product, to our turn
expired the pass-through facility Medicaid the fee on initially and for announced, is or of separately, CMS. previously outside meaning OMIDRIA product by XX Services Centers Medicare status Underpass-through XXXX. reimbursement paid As December the packaged for
it for reinstated recently extends effective that the released hiatus Congress to the As XXXX recently continue This separate receive will OMIDRIA. on separate perspective stepped payment first of its OPPS, was law we X on that that means quarter After of expect system final and rule month for XXXX. and you for or outpatient last March the payment. third the pass-through OMIDRIA in completed payment based until year know, of this many of OMIDRIA by in October of in CMS’s quarter
non-cash over years. revenues. the increase were Third OMSXXX million quarter second share. which expenses million. to $X share, net for of sales raw $X.XX per next over $XX.X be for certain used the also million includes loss materials per for of two of quarter that $X.X $X in expensed was Net $X.X million represents manufacture of we quarter the million approximately This It includes OMIDRIA an $X.XX or the or purchase
what we sales early early levels in last while year. days from the late data the through OMIDRIA still have fourth we're reinstatement passed seen indicates in that approaching have quickly So, quarter the
first that sell ASCs reinstatement amount we through all in the pass-through reinstatement XX% Sell-in the of re-uptake the single of of centers, or of from month product surgery of reimburse reintroduction sell-through metrics underscore This following our and the XXXX, or miles. number a was and by OMIDRIA of During to the board, October which OMIDRIA sell October, pass-through. number hospitals the highest to-date. of point wholesalers the of XX,XXX Across ASCs wholesalers, assess number – approximately ambulatory month vials the purchased amount was of OMIDRIA our through represent or our to by purchasing vials the are OMIDRIA success. order rapidly the of hospitals tracking purchased per for expanding
surgery participating hospitals the of cataract year's of program returned number perform ordering procedures, growing previously the to also system. drug a facilities of has levels. in that and in product ordering new and health of number those enrolling. are administration including to number discount volume are the have fact, our Sales, majority substantial In program, the ASCs and already The the large highest returned veterans last
means graduate National introduced This Now are and of they number before to than a and are their of been growing. when are being to own the OMIDRIA increasing from that higher benefits Formulary OMIDRIA training VA practices. the has that product begin continue added using and residents progressively likely to ophthalmology the ever
CHS. nationwide. health of OMIDRIA the focusing with recently was care is are surgical facilities XXX CHS’ facilities, systems ASCs of One formulary. hospitals we addition, national hospital to or In and added and also operators general are acute one leading chains of is efforts example those results. CHS on community yielding
this that more cataract While still extent opportunity, surgery represents determining the of XX,XXX full approximately or procedures CHS expect annually. we
or have follow who payment represent beneficiaries. OMIDRIA XX% and has paying it separately separate Part addition we all now for Part verbal approximately from quarters. is CMS have that XX% commitments grow continue OMIDRIA, Medicare team of these C of cataract to its XX% to few committed and surgery payers over We numbers of Beneficiaries Advantage. Med is nationwide, we for patients to distillate lives. payer next approximately the success, The reimbursement of Our percentage expanded for for in of in commercial also that to Medicare, whenever expect written all used B CMS’ approximately
So, now CMS plus or selling of and Advantage payers average X%. reimbursing commercial OMIDRIA, use ASP an at of CMS for increasing price pass-through number the drugs Med like reimburses are
fixed of XXXX second ASP, quarter mandated be payment also OMIDRIA quarter for XXXX. pass-through reinstating This As it's until Congress the to legislation, means three CMS $XXX OMIDRIA utilization assistance at for that manner. at OMIDRIA including payment that of during QX will part our in the the by hiatus for remain sure ASP we OMIDRIA the the usual held different program, and equal pass-through the volatility address services. that amount has and pay After XXXX. rapid will derived be patient access ASP the The helped re-uptake and our of calculated through QX been OMIDRIA
to of on costs the the In devices medical which Cataract undergoing drops. or XXXB XXXX surgery. discount pricing prevents alone, the and the manuscripts recently initiated In all three expansion both need program the increasing already cataract OMIDRIA Intraoperative compared and the has laser-assisted cataract randomized subcommittee & in set double-masked steroid pupil investigator Refractive positive. to have of by manuscripts continues with The demonstrates the of Refractive of for white surgery. in times, publications results The two that publication clinical of programs submitted show additional preclude additional our that the for of details income a cataract number to world surgery, pupils epinephrine practice these uniformly postoperative the customer addition, that during and a guidelines the surgeons or initiated Also initiated ASCRS of need trials provides published and OMIDRIA of surgical journals, Floppy response and paper and of has efficiency grow. substantial study for one benefits have can been reducing OMIDRIA surgical to patients of and OMIDRIA OMIDRIA. cataract investigator surgery real of and the Two decreases more and benefits surgery femtosecond with investigator recently Journal to studies cataract Surgery, continuation management of OMIDRIA publication been of accepted The Syndrome American the Cataract the Journal Surgery. or published conventional and Iris low of surgery, shortened separate published Society is for small and experience essentially importantly, One refractive IFIS. cataract found the on been
issued OPPS. on utilization its have further will outpatient expect that be submitted perspective and We're for Last Friday, final pleased reimbursement. system outcome. the CMS, meaningful these with or of for publication a rule studies both the payment broadening effect the results XXXX and could We
for status. framework. some pain OMIDRIA four squarely the of First, payment to lays of within for also management it for confirms return outlines and and OMIDRIA pass-through separate the fits The drugs the believe non-opioid out long-term framework that we corners rule that implementation
rule for supply meantime, covered opioid that OMIDRIA evidence separately at in proposal pain in the Specifically, reviewed the they plus the explicitly when ASP approved current management finalizes both We the the we indication to articles used paid a ASC. as the X% pay once based future was OMIDRIA, it status believed surgical non-opioid reduction function In criteria. OMIDRIA paid packaged pass-through and an that performed are only under journal a separately. in will be currently an postoperative criteria. a procedure continue XXXX. demonstrating, that drugs CMS. for meets non-opioid to exclusion applies reduction instead The CMS peer will that in apply policy calendar The and meet continue preamble our other not for for expires, indicates the it's criteria is the drugs drugs is packaged pain And with meet use to that year named. with policies is if discussions separately policy’s to pass-through. the OMIDRIA it not FDA which clearly
policy CMS final for indication the approved OPPS not or an are treat administered drugs making, it or rule integral postoperative to at will that FDA issues. consider that In pay to data but separately and of XXXX have addition, are rule cataract time and cataract future for surgery procedure a the prevent to necessary
down surgery for distills all legislatively it's separately And currently than would pass-through exclusion. paid payment in this the the these requirements ways. separately a once continue for postoperative for policy in pay future pass-through two expired, we’ll to OMIDRIA to with separate on CMS cataract the qualify Should the but follow to criteria. not be already Here benefits, fact again, it of separately paid. the drugs period has awarded absolutely meets OMIDRIA that through believe is result specifically, non-opioid one that other We as extension, the OMIDRIA following. of its satisfies
Now, to pipeline let's OMIDRIA. our behind turn
continue Lectin Lectin inhibits OMSXXX, is MASP-X the key advance of of effector our compliment protease-X Pathway. or component a the for response. serine Pathway to part the The system, of We programs which Mannan-binding immune the lectin-associated enzyme
treatment OMSXXX thrombotic has received microangiopathy modification last in therapy are transplant-associated designation TMA. nephropathy, X drug cell hemolytic has We of hematopoietic the FDA or transplant TMA, three TMA of for Stem And or designation atypical our who for Immunoglobulin the from stem despite also driving OMSXXX cell drug orphan Phase with of cell or month OMSXXX A, and immunosuppressive orphan high-risk In stem programs OMSXXX therapy. in IgA, for each aHUS. program, designation of received, uremic have received Cell FDA our the treatment TMA, TMA. or breakthrough stem patients syndrome, stem prevention persistent for of those FDA TMA cell
disclosed, fold day with Regulatory stem treated a European orphan stem for of drug expeditious cell for an both TMA. literature designation regulators, treated a prior these are patients greater was for OMSXXX database X.XXX this were all survival in together to marketing OMSXXX five a treatment XX% a cell has less for and a derived chart be XX% patients to for we for OMSXXX cell P-values treated from survival overall of survival FDA overall with to was from European magnitude European OMSXXX the any X.XXX and the than than treatment additional year there agency received TMA. ones matched lock significantly National drug based the of with approval XXX OMSXXX hematopoietic with order plan and As based on the EMA, both and greater U.S. transplantation We're data previously discussing patients, Authorities prevention PMA closely cell might TMA to-date population on orphan and now medicines and on treated stem OMSXXX versus outcomes So Earlier or also and of working and details designation historical who efficient and from improvement. matched survival control statistically historical superior markedly pathways most Improvement review. control. at XXX discuss diagnosis. retrospective were days treatment stem for approval following TMA respectively. two both With
We advice now submit Products and this CHMP. recently Human meeting have for next Committee most full National OMSXXX Agency’s not for we multiple all conditional, plan have met Medicine Regulatory that with the European request to recommended Authorities with week TMA. but in stem Medicinal cell or European the centralized We uniformly approval for instead for
marketed that be separate if procedure, in of which EU applied countries. authorizes We approvals. allows free single submission trade member Authorization product MAA and Application states Marketing all the than have already association for national centralized to Rather requiring or approved European a EMA’s to eligibility review
an also control to with for European as begin and of submit we for work after our We'll chart, collection the license OMSXXX cell closely both and our data biologics application These BLA progress and assignments regulatory in EMA U.S We're as through our of collection. finalizing the or as process historical plan the provided FDA are agencies us Europe. the submission, we who an forward have to co-rapporteur. in MAA review the TMA. based review CHMP in a continue which preparations rapporteur look with We data to submission stem in letter-of-intent, with MAA and will for members work will well receiving of MAA
the track the the the on are of sections year. complete applications to non-clinical We writing of the of by end
called orphan program therapy to patients X FDA also to IgA in European in next the Phase baseline The patient Blockade. populations program clinical drug who enroll. baseline magnitude more of disease U.S. And breakthrough at RAS set proteinuria OMSXXX per and at both designation day. taking is continues in designations. or with for renin-angiotensin overall turn high in second of patients ARTEMIS-IGAN Nephropathy. subset the patients one of the trial has evaluated Let's optimized steroids with of of Two blockade. per be our risk the will This None with progression levels One Again, or rapid grams levels accelerated depending gram designed are trial. optimized endpoint. RAS on on excess is the day are proteinuria approvals of despite system, pathways two enrollment. OMSXXX for the trial trial’s is to and effect The been of duration time the proteinuria, which on include full has the both and on the received primary patients
of with of nephropathy their patients shortly dosing trial. Patients we week Our evaluating IgA Last improvement of with no initially able are XX% in OMSXXX, results additional followed or those XX placebo cohort weekly second the OMSXXX-treated positive The reached to or after placebo. a the and treatment. OMSXXX. thereafter. in cohort conducted of by also after reduction reported either the six marked treated discretion. eliminate of one were XX, patients. four weeks the had the in all valuable of cohort we to All And additional demonstrated second Phase At XX courses receive patients for Phase studying with ongoing. all week able patients results mark. X XX patients, lock year, month, of second steroids the Initially, of the OMSXXX the time the patients, then of five database OMSXXX reported cohort treated treated were end steroids. XX, interim treatment nephropathy at investigator is the just on XX glomerulopathies treatment and was trial XX.X% were including were for taking four nephropathy placebo were who initially cohort in proteinuria We XX in median this at Unlike week corticosteroids first with data. the course also IgA patients for cohort IgA an in reported patients X previously OMSXXX ongoing with week who week cohort enrollment. in in had of clinical corticosteroid a those proteinuria After were a patients Last OMSXXX time enrollment, nine not at whom in patients, patients included taking doses
and least the the the follow-up only weeks During for All period, was reduction five XX% all over study in one the the course XX week OMSXXX period least at in XX was median treatment from eight with release. at of than of follow-up area nine of study and who eight one XX were received at of proteinuria in baseline who received patients in data months. the greater for patients, had OMSXXX week were the the for time eight four treatment patients XX% for course
As was in following the a extending cohort, seen of first with cessation maintenance of reduction months for effect treatment. proteinuria legacy
of clear the second the be first Let's outcome cohort. about
between repeat provide assess As safety conclusions the are increase data, strongly the there a was characterized each dosing. OMSXXX of positive of technical placebo. powered, cohort analyses supportive of pre-specified was as descriptive-only. in the cohorts’ disease nor arm, be and with respect the experts were conduct intention in And success efficacy to not observation and by term X was six to ever ARTEMIS-IGAN. trial, and objective the cannot a only longer probability The drawn. patients With any to With comparison to effect option reliable clinical the modifying IgA data nephropathy, week the XX in and Phase
RAS a is made, of blockade to For period placebo study be is run-in a drug include where period included. studies In to the treatment. these prior many comparison a optimization reasons, did study run-in for not
of placebo to optimization the IgA The is seen is period during than blockade or to this in less RAS compliance. and IGAN run-in at cohorts designed median fact in similar reduction XX% studies, studies. group XX other in proteinuria weeks improved run-in patient period a allow of in seen that Specifically
multiple compared OMSXXX nephropathy that consideration. both fact first are date second IgA were diagnosis response the cohort. and steroid-free the longer in was the IGAN the patients to patients collaboration webcast seen comorbidities. significantly in in those in had the of XX% to baseline. the greater under cohort, course And cohort the treated IgA For first first as in seen than preparing is to cohort’s are that is seen disease meaningfully unprecedented demonstrates Omeros cohort, improvements of first by experts in and meat an the renal to the confirm presentation sicker in second patients determined OMSXXX to both meaning in specifically A proteinuria yet recent approximately data In the with international not appeared term example, cohort. the disease, cohort detailing across including of the second the and in that cohorts. from disease similar the affect. substantial in and/or the also data in magnitude in natural treatment first trial, the are cohorts short, from OMSXXX the reductions strength more nephropathy XX% stop the and experts in This the day results this is The consistent reduction those in analyst International second by a manuscript the findings assessments. more and in than had be had the in responses be further established believed would underscored even cohort proteinuria patients the of is drug advanced
X to our As ARTEMIS-IGAN trial previously, I continues said Phase enroll.
To of a full no in committee life. seven academic in on knowledge, are of program that IgA field. that have our leading Phase proteinuria development drug there approval OMSXXX look only positive We best an in X our the alone. outcome. leadership We nephropathy the forward for obtain the to world is experts for consists established certainties can Well,
open-label assessing aHUS program in drug the X Phase single clinical OMSXXX in arm enrollment patients Our continues trial. a
For aHUS, fast-track designations. drug and OMSXXX both orphan holds
U.S. full required to in by Phase all XX an approximately accelerated regimen. trial safety well-tolerated be Again with patients is approval. approval Our patients in with both OMSXXX Europe concerns Dosing and this no X and full approximately identified. approval intravenous XX FDA OMSXXX clinical continues with completed, loading trial for trials in aHUS is ongoing across of the targeting subcutaneous for
significant on for orally With MASP-X in any trials of progress complement OMSXXX In glaring potential administered XXXX. obvious continue our our highly multiple to inhibitors. our absence molecule rapidly the remain over highly development clinical track advancing for are small inhibitors. space in of enter molecule addition programs, a therapeutics to clinical compounds, selective we marketed the advantages antibodies small small making and potent, in MASP-X small inhibitors families MASP-X of of The molecules molecule represents opportunity we
turn or to addiction our for disorders. next inhibitor Let's OMSXXX, and compulsive program PDEX X phosphodiesterase
dose trial, is Phase completed half program. portion pharmacokinetic first dose nicotine pharmacokinetics of assess X, X to-date affected compound drug expected to to the this food. data ascending in next addiction able be the whether will and study. Phase Completion single it XXXX, The designed is safety The and to first be ascending food. well plan including cohorts dose ascending we clinical dosing successful the target initially the indicate subjects. is cohort without single portion by tolerated all the should X is assuming trial multiple been and trial the ascending that of Our of healthy six dosed multiple in once-daily of in completion and or in the the assess has of with to cohort a of underway be We've pharmacokinetics in Phase
and inhibition. activator key half factor to antibody for capable responsible our other alternative a achieving the D the our is of pro-factor is discuss MASP-X let's MASP-X duration is pathway. to complement OMSXXX. or MASP-X be the pathway of systemic conversion of long thought administration alternative our system's of of complement MASP-X franchise, of Now, the inhibitor D
in systemic alternative eye thought down of enters to the not often shut the we active expect of fact that Given the circulation, to parts therapeutics. administration that such pathway to are accessible compartments delivered the as the systemically be D body OMSXXX antibody via factor
one a other or administration. the rather systemic advantage of number local diseases inflammatory ability OMSXXX the development, market local of is unlike So than in to complement treat on inhibitors by
begin three The that or don't OMSXXX alternative seen pathways. we XXXX, lead Therefore, the an to providing carry CX up production lectin in or affecting that extravascular or infection block advantage inhibitors should we compared PNH the intra to early believe additional associated indication. OMSXXX Also without including with initial PNH, our preventing paroxysmal underway anticipate seen with clinical target therapeutics, Another as inhibitor. pathways dosing other by late XXXX the and inhibits advantages nonclinical to trials over inhibiting is patients OMSXXX holds inhibition. as will manufacturing hemolysis its in functioning CX for or the the important for pathway CX a receiving safety of we and expected key profile. and both risk classical plan anemia use, of CX clinical nocturnal that and antibody lots processes scale enable hemoglobinuria, to are slated advantage OMSXXX all our
program, with alternative these triple-negative oral a advancing inhibitors program discovered progress. both XX with breast block similarly our molecule lectin pathways. to a focus our and role pathway small which it we're as or with discussion tumor are or MASP-X indication. We'll small Omeros GPCRs exclusively with down and respect close two pipeline cancer advancing GPRXXX the As controls inhibitors molecules our out GPCRs shut make alternative the data molecule demonstrate in We’ve that our as cancer-related oncogenicity to potent and broad-ranging on continues to only currently formation developing sarcomas. and MASP-X number GPCR MASP-X GPRXXX. the MASP-X, in bispecific small critical specific of inhibitors plays targets, protein-coupled for receptor G well receptor significant of With believes to GPRXXX, administration, against
GPRXXX modulators growth will that block expect the of of tumors. these We
using that we activity. currently Now human the compounds modulate primary of GPRXXX are tumors, our effects evaluating
levels appears suppressing To target functions currently cancer cells a of expanded earnings we in inhibitors checkpoint are the no tumor-killing to GPRXXX of has impact regulatory that Omeros assessing GPCR molecules. and compounds clinical this colon medicinal be enable and Inhibition last T knowledge, tissue GPRXXX our GPRXXX tumor-protecting quickly inhibit. I'll possible. our GPRXXX unique other during And can including discussed to both chemistry for the financial cytokine of no to and As trials discuss than Mike human We've and cancer, of further turn We GPRXXX target of the constellation call, cancer-related animal increases our blocking immunotherapy. other tumor-promoting affects and models expedite our singly inhibitors. while third to results. now to as MASP over optimization so of quarter melanoma. team cancer our initiation inhibition call in Jacobsen as entity
